Oligonucleotides Analytical Development & CMC

The 5th Oligonucleotide Analytical Development & CMC Summit returns to Boston as a leading end-to-end forum for oligonucleotide AD & CMC. Bringing together analytical, CMC, and regulatory leaders, the summit aims to help define the roadmap for successful oligonucleotide development.

The 2026 program highlights key topics such as analytical development, impurity profiling, CMC strategy, quality, GMP, process development, formulation, stability, and regulatory perspectives. It is designed to support drug developers in confidently characterizing, controlling, and scaling high-quality oligonucleotide therapeutics towards approval.

We’ll also be contributing to the program, with Tim Hellenbrand, Senior Group Leader QC, presenting – further details will follow soon.

Let’s connect in Boston from 17-19 August!